Omeros Reports Additional Positive Clinical Data for its Drug Candidate to Treat Cognitive Disorders

— PDE10 Target Engagement Continues to Increase with Well-Tolerated Doses –

 SEATTLE, Oct. 17, 2013 /PRNewswire/ — Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros’ phosphodiesterase 10 (PDE10) program. This latest clinical trial evaluated the extent to which OMS824, at a dose higher than previously reported, binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. OMS824 achieved an average of 63-percent engagement at PDE10 and did not trigger the dose-limiting side effects seen with other PDE10 inhibitors. These data further support advancing OMS824 through clinical trials in patients with cognitive disorders. Last month, Omeros started a Phase 2 trial evaluating the drug in patients with schizophrenia and plans to start a Phase 2 trial in Huntington’s disease later this year.

The results reported today were in healthy male subjects receiving OMS824 once daily for seven days at a dose higher than those previously evaluated in the target-engagement clinical trial. Positron emission tomography (PET) scans were used to measure the binding activity of OMS824 to PDE10 in the brain. An average of 63-percent occupancy at PDE10 was seen in the basal ganglia, the region of the brain that plays a critical role in cognition. The drug was well tolerated with mild somnolence as the only apparent side effect.

While the level of target engagement seen in this PET trial is significantly higher with lesser side effects than has been reported for any other PDE10 inhibitor in development, a recently completed Phase 1 clinical pharmacokinetic trial with 10 days of OMS824 dosing achieved approximately 50 percent higher plasma concentrations than in the PET trial, and all side effects were mild and well-tolerated, and most were self-limiting. PET data were not obtained in this pharmacokinetic trial but, based on modeling of all data obtained in the OMS824 Phase 1 program, it is estimated that the drug engaged the PDE10 enzyme at levels substantially greater than 63 percent. Omeros is now planning to evaluate a higher dose of OMS824 in the PET trial to confirm this estimate.

Effective inhibition of PDE10 is considered a novel and promising mechanism to treat Huntington’s disease, schizophrenia and other central nervous system disorders. Omeros was recently awarded Orphan Drug Designation by the US Food and Drug Administration to evaluate OMS824 in Huntington’s disease and a Fast Track application to the FDA is currently under review. The company plans to begin enrollment in a Phase 2 clinical trial in Huntington’s disease before year-end, and a Phase 2 clinical trial is already underway in schizophrenia.

“We are encouraged by the continued stream of positive data from our PDE10 program,” stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “PDE10 is an exciting target for the treatment of cognitive disorders, and OMS824 is being recognized for attributes that appear to be superior to those of other PDE10 inhibitors in development. We look forward to reviewing the series of data from our ongoing programs in patients suffering from Huntington’s disease and schizophrenia.”


About Omeros’ PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington’s disease and schizophrenia. Huntington’s disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Schizophrenia is a group of severe brain disorders characterized by an abnormal interpretation of reality, which can manifest as delusions, hallucinations, and/or disordered thinking and behavior. Cognitive dysfunction is responsible for substantial disability in both of these diseases and is not meaningfully improved by current medications. Omeros’ proprietary compound OMS824, currently in Phase 2 clinical programs, inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve the motor and psychiatric abnormalities in Huntington’s disease as well as the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of schizophrenia. Omeros was recently awarded Orphan Drug Designation by the US FDA to evaluate OMS824 in Huntington’s disease and a Fast Track application to the FDA is currently under review.


Source: Omeros Corporation

4 Condivisioni